Alcidion FY27 Contracted Revenue $50.0M, Up 38%

Alcidion (ASX:ALC) issued a trading update to keep the market informed now that it is no longer required to lodge quarterly Appendix 4C reports, reporting higher contracted revenue for FY27 and reconfirming its guidance.

As of 30 September 2026, FY27 contracted (sold & renewal) revenue was $50.0M, up 38% on the prior corresponding period, which the company describes as a record. An expanded contract with Northern Care Alliance NHS Foundation Trust moves the Trust from ExtraMed Flow products to Miya and adds sites, with a Total Contract Value of $7.5M over 3 years, options to extend up to 5 years, and $4.5M expected to be recognised in FY27. Health NZ MidCentral has expanded its contract to include Whanganui Hospital. Alcidion announced Miya Patient Administration, an AI-enabled patient administration system, and says integration of the Kyra flow products business is progressing, with cost synergies being delivered through FY27. An on-market buy-back of up to 10% of issued capital, approximately 135 million shares, is expected to commence on or around 10 November 2026, and a consolidation of every 10 shares into 1 share is subject to shareholder approval.

Guidance is only that FY27 revenue and Underlying EBITDA will exceed FY26; the release does not state figures for either. The 10% buy-back limit is a maximum, not a commitment to purchase.